Supplementary Table S4 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Jianxiang Wang

DOI: https://doi.org/10.1158/1078-0432.27938347

2024-01-01

Abstract:Supplementary Table 4. The concordance of four methods for MYD88 mutation detection

What problem does this paper attempt to address?

Supplementary Table S7 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938335

2024-01-01

Abstract:Supplementary Table 7. The concordance of three methods for CXCR4 mutation detection
Supplementary Table S3 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938350

2024-01-01

Abstract:Supplementary Table 3. The test performance of four methods in detection of MYD88 mutations.
Supplementary Table S6 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938338

2024-01-01

Abstract:Supplementary Table 6. The test performance of three methods in detection of CXCR4 mutations
Supplementary Table S5 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938344

2024-01-01

Abstract:Supplementary Table 5. Detection of MYD88 and CXCR4 mutation by different methods, NGS, next generation sequencing; AS-PCR, real-time
Supplementary Methods S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938368

2024-01-01

Abstract:Supplementary Table 1. Summary of the regimens for this cohort.
Supplementary Table S10 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938359

2024-01-01

Abstract:Supplementary Table 10. The response rate by MYD88/CXCR4 genotype during first-line BTKi-based therapy.
Supplementary Table S2 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938353

2024-01-01

Abstract:Supplementary Table 2. Clinical characteristics and first-line treatment options for the entire symptomatic Waldenstrom macroglobulinemia (WM) cohort (n = 385) and for patients available for analysis of treatment response and outcome (n = 336).
Supplementary Figure S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938398

2024-01-01

Abstract:Supplementary Figure 1. Mutation rates of MYD88 in patients with different tumor load detected by (A) Sanger sequencing; (B) next generation sequencing (NGS); (C) real-time allele specific polymerase chain reaction (AS-PCR); (D) droplet digital polymerase chain reaction (ddPCR). ns, no significance; ***P < 0.001.
Supplementary Figure S6 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938383

2024-01-01

Abstract:Supplementary Figure 6. Survival outcomes for the entire cohort. (A) The progression free survival of the entire cohort; (B) The overall survival of the entire cohort.
Supplementary Figure S4 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938389

2024-01-01

Abstract:Supplementary Figure 4. The IGHV-D-J repertoire in patients with mutated and wild-type CXCR4. Distribution of major VH family gene segments in CXCR4 wild-type group (A) and CXCR4 mutated group (B); Distribution of major DH family gene segments in CXCR4 wildtype group (C) and CXCR4 mutated group (D); Distribution of major JH family gene segments in CXCR4 wild-type group (E) and CXCR4 mutated group (F)
Supplementary Figure S2 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938395

2024-01-01

Abstract:Supplementary Figure 2. The IGHV-D-J repertoire in patients with mutated and wild-type MYD88. Distribution of major VH family gene segments in wild-type group (A) and mutated group (B); Distribution of major DH family gene segments in wild-type group (C) and mutated group (D); Distribution of major JH family gene segments in wild-type group (E) and mutated group (F)
Supplementary Figure S8 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938374

2024-01-01

Abstract:Supplementary Figure 8. The survival outcomes of patients with MYD88/CXCR4 mutation status according to the option of different first-line therapies. The progression free survival and overall survival in patients with cytotoxic therapy (A-B); in patients with Rtuximab/bortezomib-based therapy; (C-D); and in patients with BTKi-based therapy (E-F). *P < 0.05, **P < 0.01, ***P < 0.001.
Supplementary Figure S9 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao,Yujiao Jia,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lyu,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.27938371

2024-01-01

Abstract:Supplementary Figure 9. The survival of patients according to IPSSWM risk model. (A) The overall survival of the whole cohort; (B) The overall survival in patients treated with BTKi-based therapy
Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia

Yuting Yan,Ying Yu,Wenjie Xiong,Jun Wang,Yao Yao,YUJIAO JIA,Yanshan Huang,Yuxi Li,Tingyu Wang,Rui Lv,Hao Sun,Haoxu Wang,Qi Wang,Wei Liu,Gang An,Weiwei Sui,Yan Xu,Wenyang Huang,Zhen Yu,Dehui Zou,Mu Hao,Zhijian Xiao,Jianxiang Wang,Lugui Qiu,Shuhua Yi

DOI: https://doi.org/10.1158/1078-0432.ccr-23-3939

IF: 13.801

2024-10-09

Clinical Cancer Research

Abstract:Purpose: This study aims to explore the incidence and clinical features of MYD88 and CXCR4 mutations in patients with Waldenström macroglobulinemia (WM) and determine the optimal method for routine clinical practice. Additionally, we seek to evaluate the prognostic significance of these features across various therapeutic backgrounds [cytotoxic group, the Rituximab/Bortezomib-based group, and the Bruton's tyrosine kinase inhibitor (BTKi) group]. Experimental Design: 385 symptomatic WM patients were analyzed for MYD88 and CXCR4 mutations using Sanger sequencing, next-generation sequencing (NGS), allele-specific quantitative polymerase chain reaction (AS-PCR), and/or droplet digital PCR (ddPCR). Results: The overall MYD88 mutation rate was 87.8%, relatively lower than that in Western cohort. Both AS-PCR and ddPCR demonstrated high sensitivity in unsorted samples, detecting 98.5% and 97.7% of mutations, respectively, including those with low tumor burdens. The total CXCR4 mutation rate was 30.9%, with NGS exhibiting the highest sensitivity of 78.0%. CXCR4 mutation was significantly linked to shorter OS only within the BTKi treatment group. The multivariate analysis indicated that MYD88 and CXCR4 mutations were not independent prognostic factors in the non-BTKi group when considering IPSSWM clinical staging. However, in the BTKi treatment group, these mutations emerged as independent adverse prognostic factors, overshadowing the prognostic significance of IPSSWM classification (MYD88: HR=0.229, P=0.030; CXCR4: HR=3.349, P=0.012). Conclusions: Testing for MYD88 mutations using AS-PCR or ddPCR in unsorted samples is viable for routine clinical practice. Under BTKi treatment, MYD88 and CXCR4 mutations hold greater prognostic importance than IPSSWM staging in WM.

oncology
Detection of the MYD88L265P and CXCR4S338X Mutations by Cell-Free DNA in Waldenström Macroglobulinemia

Yan-Yan Wu,Ming-Nan Jia,Hao Cai,Yu Qiu,Dao-Bin Zhou,Jian Li,Xin-Xin Cao

DOI: https://doi.org/10.1007/s00277-020-04139-7

2020-01-01

Annals of Hematology

Abstract:We aimed to detect the MYD88L265P and CXCR4S338X mutations in cell-free DNA (cfDNA) in patients with Waldenström macroglobulinemia (WM). We collected peripheral blood and paired bone marrow aspirates from 27 WM patients (including 16 patients with newly diagnosed WM, 3 patients with WM in relapse and 8 patients with WM during treatment). cfDNA was extracted from peripheral blood using a QIAamp Circulating Nucleic Acid Kit. The MYD88L265P and CXCR4S338X mutations were detected by real-time allele-specific PCR (AS-PCR) in cfDNA and genomic DNA (gDNA) extracted from bone marrow aspirates. The sensitivity of real-time AS-PCR for detecting MYD88L265P in cfDNA was determined using a serial dilution of 10%, 2%, 0.4% and 0.08% MYD88L265P cfDNA in wild-type cfDNA. Among the 27 patients, MYD88L265P was detected in 88.9% of them in gDNA and in 85.2% of them in cfDNA, with a concordance rate of 96.3%. The concordance rates were 93.8%, 100% and 100% in patients with newly diagnosed WM, patients with WM in relapse and patients with WM during treatment, respectively. The sensitivity of real-time AS-PCR for detecting MYD88L265P in cfDNA was 0.4%. CXCR4S338X was detected in 6.3% of the 16 newly diagnosed WM patients in both gDNA and cfDNA, with a concordance rate of 100.0%. It is feasible to apply cfDNA to detect MYD88L265P and CXCR4S338X in WM patients with a high concordance rate.
[Evaluation of Clinical Characteristics, MYD88(L265P) Mutation, CXCR4(WHIM) Mutation and Prognosis in Waldenström Macroglobulinemia: A Single Center Retrospective Study of 93 Patients].

X,Q Meng,H Cai,Y,M H Duan,T N Zhu,W Zhang,B Han,J L Zhuang,H C Cai,M Chen,J Feng,X Han,Y Zhang,C Yang,L Zhang,D B Zhou,J Li

DOI: https://doi.org/10.3760/cma.j.issn.0253-2727.2017.06.006

2017-01-01

Abstract:Objective: To evaluate the clinical characteristics, MYD88(L265P) mutation, CXCR4(W)HIM mutation and prognosis in patients with Waldenström macroglobulinemia (WM). Methods: The clinical characteristics, International Prognostic Scoring System for symptomatic WM (WPSS) , and overall survival (OS) were retrospectively assayed in 93 patients with newly diagnosed WM at Peking Union Medical College Hospital during January 2000 to August 2016. The MYD88(L265P) mutation and CXCR4(W)HIM mutation were tested among 34 patients. Results: The median age of the 93 patients was 64 years (range, 33-85 years) with a male-to-female ratio of 2.44. According to WPSS, we included 16 (17.2%) low-risk, 44 (47.3%) intermediate-risk and 33 (35.5%) high-risk patients. Eight patients had secondary amyloidosis. With a median follow-up of 44 (1-201) months, the median OS was 84 months. Cox regression multifactor analysis showed WPSS risk group (HR=2.342, 95% CI 1.111-4.950, P=0.025) , whether patients had secondary amyloidosis (HR=5.538, 95% CI 1.958-15.662, P=0.001) and whether patients received new drugs (HR=3.392, 95% CI 1.531-7.513, P=0.003) were independent factors associated with OS. We have investigated the presence of the MYD88(L265P) and CXCR4(WHIM) mutation in 34 patients and found that MYD88(L265P) mutation was occurred in 32 patients (94.1%) and CXCR4(WHIM) mutation was occurred in 8 patients (23.5%). Seven of 8 patients who harbored CXCR4(WHIM)-mutated also exhibited the MYD88(L)265P mutation. Patients with MYD88(L265P)CXCR4(WHIM) vs MYD88(L265P)CXCR4(WT) presented with more severe anemia, lower platelet level, higher M protein level and more hyper-viscosity syndrome. Conclusion: WPSS risk group, whether patients had secondary amyloidosis or received new drugs are independent factors for OS in WM. MYD88(L265P) and CXCR4(WHIM) mutation, the most common somatic variants in WM, often occur together and impact the clinical presentation.
Figure S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Gang An,Daobin Zhou,Shu Cheng,Keshu Zhou,Jianyong Li,Jianfeng Zhou,Liping Xie,Jie Jin,Liye Zhong,Lingzhi Yan,Haiyi Guo,Chenmu Du,Jinhua Zhong,Yiling Yu,Binghao Wu,Lugui Qiu

DOI: https://doi.org/10.1158/1078-0432.27328057

2024-01-01

Abstract:Median immunoglobulin M and hemoglobin over time in Chinese patients with R/R WM receiving zanubrutinib.
Detection of Myd88 L265p and Whim-Like Cxcr4 Mutation in Patients with Igm Monoclonal Gammopathy Related Disease

Xin-xin Cao,Qi Meng,Hao Cai,Tian-Hua He,Cong-li Zhang,Wei Su,Jian Sun,Yue Li,Wei Xu,Dao-bin Zhou,Jian Li

DOI: https://doi.org/10.1007/s00277-017-2968-z

2017-01-01

Annals of Hematology

Abstract:Objectives The presence of IgM monoclonal gammopathy can occur in a broad spectrum of diseases, including Waldenstrom macroglobulinemia (WM), various B cell non-Hodgkin9s lymphoma (NHL), monoclonal gammopathy of undetermined significance (MGUS), and so on. MYD88 L265P and WHIM-like CXCR4 mutation are highly prevalent in WM. However, the data is lacking in other IgM monoclonal gammopathy related diseases (IgM-RD). Therefore we investigated MYD88 L265P and WHIM-like CXCR4 mutation in various IgM-RD. Methods Patients with sIFE confirmed IgM monoclonal gammopathy and had enough material for DNA extraction between January 2008 and May 2016 at Peking Union Medical College Hospital were enrolled in this cohort. Bone marrow samples or paraffin-embedded tumor tissues were collected. We performed Real-time allele-specific-polymerase chain reaction (AS-PCR), AS-PCR and Sanger sequencing to explore the presence of MYD88 L265P and WHIM-like CXCR4 mutation. Results Ninety-three patients (51 male and 42 female patients) were included in this retrospective study. Median age at diagnosis was 62 years (range, 30-84 years). As for the type of light chain, 65 patients were IgM kappa (69.9%), 28 patients were IgM lambda (30.1%). The median level of serum IgM was 7.9g/L (range, 0.6-104.0g/L). There were 32 patients (34.4%) diagnosed with WM, 5 patients (5.4%) diagnosed with smoldering WM (sWM), 38 patients (40.9%) diagnosed with B cell NHL and 9 patients (9.7%) were diagnosed with MGUS. We outlined the main diagnosis, clinical characteristics and MYD88 L265P, WHIM-like CXCR4 mutation of the 93 patients in Table 1. MYD88 L265P mutation was detected in 30/32 (93.8%) patients with WM, 2/5 (40%) with sWM, 4/9 (44.4%) with IgM-MGUS, 6/14 (42.9%) with diffuse large B cell lymphoma (DLBCL), 2/6 (33.3%) with marginal zone lymphoma (MZL), 3/5 (60%) with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), 1/7 (4.3%) with mucosa-associated lymphoid tissue lymphoma (MALT), 1/2 (50%) with mantle cell lymphoma (MCL), 1/1 patients with primary amyloidosis (AL) and 1/1 patients with Castleman disease (CD). WHIM-like CXCR4 mutation was detected 7/32 (21.9%) patients with WM, 1/5 (20%) with sWM and 1/14 (7.1%) with DLBCL. Conclusion IgM monoclonal gammopathy is most frequently found in WM, but it contains a broad spectrum of diseases. MYD88 L265P mutation is highly prevalent in WM and IgM MGUS, and the prevalence of MYD88 mutation in IgM related NHL is higher than that in not specified NHL reported in the literature. WHIM-like CXCR4 mutation is common in WM, but rare in other IgM-RD. Disclosures No relevant conflicts of interest to declare.
Figure S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Gang An,Daobin Zhou,Shu Cheng,Keshu Zhou,Jianyong Li,Jianfeng Zhou,Liping Xie,Jie Jin,Liye Zhong,Lingzhi Yan,Haiyi Guo,Chenmu Du,Jinhua Zhong,Yiling Yu,Binghao Wu,Lugui Qiu

DOI: https://doi.org/10.1158/1078-0432.27328063

2024-01-01

Abstract:Mutation status and bone marrow involvement by biopsy at baseline in Chinese patients with R/R WM.
Treatment and Outcome Patterns of Patients with Waldenström’s Macroglobulinemia: a Large, Multicenter Retrospective Review in China

Xinxin Cao,Shuhua Yi,Zhongxing Jiang,Jingsong He,Wei Yang,Juan Du,Chaoyang Sun,Yuzhang Wu,Wen-Ming Chen,Xiaojun Liu,Bing-Zong Li,Chunrui Li,Wei Sang,Qinhua Liu,Xiaoxia Chu,Fēi Li,Ou Bai,Min Mao,Rong Fu,Wei Wang,Lihong Liu,Luqun Wang,Yujun Dong,Jun Luo,Zhenling Li,Yongqiang Wei,Qi‐Ke Zhang,Jing Liu,Kaiyang Ding,Liang Zou,Biyun Chen,Luoming Hua,Hongmei Jing,Jiahui He,Liang Wang,Jian Li,Lugui Qiu

DOI: https://doi.org/10.1080/10428194.2021.1938030

2021-01-01

Abstract:In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in 22 provinces of China. Fifty-four patients (7.3%) received monotherapy, 264 (36.0%) received chemoimmunotherapy, 395 (53.8%) received other combination regimens without rituximab, and 21 (2.9%) received ibrutinib. Using a multivariable Cox regression model, age > 65 years old, platelets <100 × 109/L, serum albumin <3.5 g/dl, β2 microglobulin concentration ≥4 mg/L and LDH ≥250 IU/L predicted poor OS. In summary, our study showed that frontline treatment choices for WM are widely heterogeneous. We validated most of the established prognostic factors in the rIPSS (age >65 years, LDH ≥250 IU/L, ALB <3.5 g/dl and β2 microglobulin ≥4 mg/L) together with PLT ≤ 100 × 109/L indicate a poor prognosis for patients with WM.

Supplementary Table S4 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S7 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S3 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S6 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S5 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Methods S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S10 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Table S2 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S1 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S6 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S4 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S2 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S8 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Supplementary Figure S9 from Determination of MYD88 and CXCR4 Mutations for Clinical Detection and Their Significance in Waldenström Macroglobulinemia

Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenström macroglobulinemia

Detection of the MYD88L265P and CXCR4S338X Mutations by Cell-Free DNA in Waldenström Macroglobulinemia

[Evaluation of Clinical Characteristics, MYD88(L265P) Mutation, CXCR4(WHIM) Mutation and Prognosis in Waldenström Macroglobulinemia: A Single Center Retrospective Study of 93 Patients].

Figure S3 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Detection of Myd88 L265p and Whim-Like Cxcr4 Mutation in Patients with Igm Monoclonal Gammopathy Related Disease

Figure S1 from A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia

Treatment and Outcome Patterns of Patients with Waldenström’s Macroglobulinemia: a Large, Multicenter Retrospective Review in China